Vanda Pharmaceuticals Inc (VNDA) Q4 2024 Earnings Call Highlights: Revenue Growth Amidst Challenges
Vanda Pharmaceuticals Inc (VNDA) reports strong Fanapt sales growth and strategic initiatives, despite facing increased ...
Vanda Pharmaceuticals targets total annual revenue in excess of $1B in 2030
For the psychiatry portfolio alone, Vanda is targeting annual revenue in excess of $750M in 2030, assuming the potential approval of Bysanti ...
Vanda Pharmaceuticals sees FY25 revenue $210M-$250M, consensus $284.9M
M, consensus $284.9M Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and ...
H.C. Wainwright lifts AnaptysBio stock target to $22, keeps Neutral
H.C. Wainwright analyst Emily Bodnar increased the price target on AnaptysBio (NASDAQ:ANAB) shares to $22.00, up from the previous $19.00, while maintaining a Neutral rating on the stock. According to ...
FierceBiotech2d
AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2 trial
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
Rosnilimab shows promise in rheumatoid arthritis trial
SAN DIEGO - AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company currently trading near its 52-week low at $12.38, announced significant findings from their Phase 2b RENOIR trial for ...